These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26506237)

  • 1. Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemia.
    Shi JL; Fu L; Ang Q; Wang GJ; Zhu J; Wang WD
    Oncotarget; 2016 Jan; 7(3):2585-95. PubMed ID: 26506237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
    Shi JL; Fu L; Wang WD
    Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
    Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
    J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia.
    Fu L; Shi J; Hu K; Wang J; Wang W; Ke X
    Oncotarget; 2015 Apr; 6(10):8144-54. PubMed ID: 25924238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
    Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
    Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia.
    Fu L; Fu H; Tian L; Xu K; Hu K; Wang J; Wang J; Jing H; Shi J; Ke X
    Oncotarget; 2016 Mar; 7(13):15828-39. PubMed ID: 26910834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemia.
    Jinlong S; Lin F; Yonghui L; Li Y; Weidong W
    PLoS One; 2015; 10(2):e0118099. PubMed ID: 25646775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia.
    Shi J; Fu H; Jia Z; He K; Fu L; Wang W
    EBioMedicine; 2016 Dec; 14():55-64. PubMed ID: 27916548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel molecular markers for prognosis estimation of acute myeloid leukemia: over-expression of PDCD7, FIS1 and Ang2 may indicate poor prognosis in pretreatment patients with acute myeloid leukemia.
    Tian Y; Huang Z; Wang Z; Yin C; Zhou L; Zhang L; Huang K; Zhou H; Jiang X; Li J; Liao L; Yang M; Meng F
    PLoS One; 2014; 9(1):e84150. PubMed ID: 24416201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.
    Metzeler KH; Dufour A; Benthaus T; Hummel M; Sauerland MC; Heinecke A; Berdel WE; Büchner T; Wörmann B; Mansmann U; Braess J; Spiekermann K; Hiddemann W; Buske C; Bohlander SK
    J Clin Oncol; 2009 Oct; 27(30):5031-8. PubMed ID: 19752345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower expression of bone marrow miR-122 is an independent risk factor for overall survival in cytogenetically normal acute myeloid leukemia.
    Zhang TJ; Qian Z; Wen XM; Zhou JD; Li XX; Xu ZJ; Ma JC; Zhang ZH; Lin J; Qian J
    Pathol Res Pract; 2018 Jun; 214(6):896-901. PubMed ID: 29627222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
    Marcucci G; Maharry K; Whitman SP; Vukosavljevic T; Paschka P; Langer C; Mrózek K; Baldus CD; Carroll AJ; Powell BL; Kolitz JE; Larson RA; Bloomfield CD;
    J Clin Oncol; 2007 Aug; 25(22):3337-43. PubMed ID: 17577018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prognostic Significance of PDE7B in Cytogenetically Normal Acute Myeloid Leukemia.
    Cao L; Zhang W; Liu X; Yang P; Wang J; Hu K; Zhang X; Liu W; He X; Jing H; Yuan X
    Sci Rep; 2019 Nov; 9(1):16991. PubMed ID: 31740742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia.
    Metzeler KH; Heilmeier B; Edmaier KE; Rawat VP; Dufour A; Döhner K; Feuring-Buske M; Braess J; Spiekermann K; Büchner T; Sauerland MC; Döhner H; Hiddemann W; Bohlander SK; Schlenk RF; Bullinger L; Buske C
    Blood; 2012 Sep; 120(10):2118-26. PubMed ID: 22815426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher Expression of
    Chen C; Chen Z; Chio CL; Zhao Y; Li Y; Liu Z; Jin Z; Wu X; Wei W; Zhao Q; Li Y
    Technol Cancer Res Treat; 2021; 20():15330338211052152. PubMed ID: 34738847
    [No Abstract]   [Full Text] [Related]  

  • 16. A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia.
    Metzeler KH; Maharry K; Kohlschmidt J; Volinia S; Mrózek K; Becker H; Nicolet D; Whitman SP; Mendler JH; Schwind S; Eisfeld AK; Wu YZ; Powell BL; Carter TH; Wetzler M; Kolitz JE; Baer MR; Carroll AJ; Stone RM; Caligiuri MA; Marcucci G; Bloomfield CD
    Leukemia; 2013 Oct; 27(10):2023-31. PubMed ID: 23765227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low NKD1 expression predicts adverse prognosis in cytogenetically normal acute myeloid leukemia.
    Zhou JD; Yao DM; Han L; Xiao GF; Guo H; Zhang TJ; Li XX; Yuan Q; Yang L; Lin J; Qian J
    Tumour Biol; 2017 Apr; 39(4):1010428317699123. PubMed ID: 28443469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
    Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
    Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML.
    Sun SM; Rockova V; Bullinger L; Dijkstra MK; Döhner H; Löwenberg B; Jongen-Lavrencic M
    Leukemia; 2013 Jan; 27(1):100-6. PubMed ID: 22692398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
    Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
    J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.